- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07619898
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure (PHOENIX-ECP)
PHOENIX- A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis or Hepatitis With Inadequate Response to Corticosteroids in Participants With Unresectable or Metastatic Melanoma Treated With Immune Checkpoint Inhibitors (ICI)
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also known as UVADEX) is used in combination with ultraviolet A (UVA) light.
Immune checkpoint inhibitor therapy is widely used for the treatment of several cancers, including melanoma. However, a common immune-related adverse event associated with this therapy is Immune-related colitis or hepatitis. Corticosteroids are typically the first-line treatment for this condition, but some participants do not respond adequately.
The purpose of this study is to evaluate the efficacy of ECP in the treatment of immune-related (ir)-colitis and ir-hepatitis with inadequate response to corticosteroids, and to compare its efficacy to other second-line immunosuppressant therapies. The ECP procedure in this study is performed using the CELLEX® device, a fully closed-loop extracorporeal blood circulation device. The CELLEX device is used in conjunction with methoxsalen.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Therakos TKS2001 Study Team
- Telefonnummer: 855-512-3327
- E-post: Clinicaltrials@therakos.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Participants diagnosed with unresectable or metastatic melanoma ( Stage III and Stage IV) received ICI treatment (e.g., anti-PD-1, anti-PD-L1, anti-LAG-3, anti-CTLA-4 antibody, as ICI monotherapy or ICI combination therapy) and ICI paused or discontinued because of the development of ir-colitis or ir-hepatitis.
- Participants diagnosed with ir-colitis and/or ir-hepatitis with a severity of Grade 2 or higher, based on ASCO Guidelines (
- Participants with endoscopic evidence of ir-colitis
- Participants with inadequate response to corticosteroids, as defined per protocol
- Participants who have Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
Exclusion Criteria:
- Presence of irAEs in addition to and other than ir-colitis and/or ir-hepatitis, with a higher severity grade than the irAE for inclusion (ir-colitis/ir-hepatitis) based on ASCO guidelines.
- Participant has a diagnosis of uveal melanoma as the sole melanoma subtype
- Treatment of ir-colitis or ir-hepatitis with any systemic therapy other than corticosteroids
- Concurrent conditions which may require treatment with high dose corticosteroid (> 1 milligram per kilogram per day [mg/kg/day]) and interfere with the corticosteroid tapering schedule recommended by the protocol.
- Pre-existing liver disease
- Active alcohol use disorder
- Concomitant treatment with any chemotherapy or targeted therapy for the treatment of unresectable or metastatic melanoma.
- Use of any investigational agent within 5 half-lives of the investigational agent prior to randomization.
- Contraindications or known allergic reaction to any of study intervention and/or procedures
- Participants unable to tolerate the fluid shift associated with the ECP procedure.
- Positive result for active or previous viral infections: covid-19, hepatitis B/C, CMV, EBV, adenovirus
- History of previous or concurrent malignancies within the last 3 years, other than unresectable or metastatic melanoma.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Methoxsalen in Conjunction with Extracorporeal Photopheresis System (ECP)
Participants will receive methoxsalen, in conjunction with ECP
|
Sterile solution used in conjunction with CELLEX ECP
Andre navn:
Methoxsalen is used in conjunction with the CELLEX ECP
Andre navn:
|
|
Aktiv komparator: Best Available Therapy (BAT)
Participants with ir-colitis will receive either Infliximab or Vedolizumab as per the investigator's choice.
Participants with ir-hepatitis will receive Mycophenolate Mofetil (MMF) or Azathioprine as per the investigator's choice.
|
Vedolizumab will be administered intravenously
Infliximab will be administered intravenously
Mycophenolate Mofetil will be administered orally or intravenously
Azathioprine will be administered orally or intravenously
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Proportion of Participants Who are in Steroid-free response at Week 12 for the Randomized Immune-related Adverse Event (irAE) (ir-colitis or ir-hepatitis)
Tidsramme: Week 12
|
Week 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of irAE response
Tidsramme: Week 64
|
Time from the start of irAE response to either the relapse of irAE (if relapse occurs), or a censoring event.
|
Week 64
|
|
Progression Free Survival (PFS) for Melanoma
Tidsramme: Week 64
|
Week 64
|
|
|
Overall Survival (OS)
Tidsramme: Week 64
|
Week 64
|
|
|
Proportion of Participants With at Least Stable Disease as Assessed by RECIST 1.1 at Week 12 and During Follow-up
Tidsramme: Week 12 and Week 64
|
Week 12 and Week 64
|
|
|
Proportion of Participants with Treatment-Emergent Adverse Event (TEAEs) per Common Toxicity Criteria for Adverse Events (CTCAE) v5.0
Tidsramme: From first dose of the study drug up to end of study (up to Week 64)
|
From first dose of the study drug up to end of study (up to Week 64)
|
|
|
Cumulative Systemic Corticosteroid Exposure From Randomization to Week 12
Tidsramme: Up to Week 12
|
Up to Week 12
|
|
|
Peak Dose of Systemic Corticosteroid Exposure From Randomization to Week 12
Tidsramme: Up to Week 12
|
Up to Week 12
|
|
|
Proportion of Participants who Completely Discontinue Systemic Corticosteroid Treatment Until Week 12
Tidsramme: Week 12
|
Week 12
|
|
|
Time to Complete Discontinuation of Systemic Corticosteroids for at Least 1 Week
Tidsramme: From screening up to the first documentation of the discontinuation of systemic corticosteroid (up to Week 64)
|
From screening up to the first documentation of the discontinuation of systemic corticosteroid (up to Week 64)
|
|
|
Time to First Response of Randomized irAE Based on ASCO Criteria
Tidsramme: Week 64
|
Week 64
|
|
|
Proportion of Participants With at Least one irAE who Achieve Response (as Defined per ASCO Criteria) at Week 12
Tidsramme: Week 12
|
Week 12
|
|
|
Proportion of Participants With at Least One irAE That Resolves Completely (as per CTCAE v5.0) and Remains Resolved Until Week 12
Tidsramme: Week 12
|
Week 12
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Isabelle T Seemann, Ph.D, Therakos LLC
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- Tilfeldig kontrollert test
- Melanom
- Enhet
- Metastatisk melanom
- Uopererbart melanom
- ECP
- Kolitt
- Immunrelaterte bivirkninger
- Immunrelatert kolitt
- Fase 2 klinisk studie
- Ekstrakorporeal fotoferese
- Metokssalen
- Steroid-ildfast
- Immune checkpoint inhibitor toxicity
- Checkpoint inhibitor-induced colitis
- Checkpoint inhibitor-induced hepatitis
- Immune checkpoint Inhibitors
- UVADEX
- Corticosteroid refractory
- Cellex
- 8-Mop
- Ir-AE
- Ir-AE Colitis
- Ir-AE Hepatitis
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Tarmsykdommer
- Neoplasmer etter histologisk type
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Leversykdommer
- Kolonsykdommer
- Hudsykdommer
- Gastroenteritt
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Nevroendokrine svulster
- Nevi og melanomer
- Neoplasmer i huden
- Hud- og bindevevssykdommer
- Hepatitt
- Kolitt
- Melanom
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Terapeutikk
- Pyraner
- Fettsyrer
- Lipider
- Kirurgiske prosedyrer, operativ
- Nukleinsyrer, nukleotider og nukleosider
- Syrer, acyklisk
- Karboksylsyrer
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Puriner
- Nukleosider
- Kumariner
- Benzopyraner
- Caproates
- Fototerapi
- Heterocykliske forbindelser, 3-ring
- Ekstrakorporeal sirkulasjon
- PUVA -terapi
- Ultraviolett terapi
- Furocoumarins
- Tionukleosider
- Mercaptopurine
- Infliximab
- Mykofenolsyre
- Azatioprin
- Metokssalen
- Vedolizumab
- Fotoferese
Andre studie-ID-numre
- TKS2001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .